135 related articles for article (PubMed ID: 31977693)
1. Evaluation and Factors of Quality of Life Among Patients With Neurofibromatosis Type 1-Associated Craniofacial Plexiform Neurofibromas.
Ren JY; Gu YH; Wei CJ; Huang X; Xu XW; Gu B; Zan T; Wang ZC; Li QF
J Craniofac Surg; 2020; 31(2):347-350. PubMed ID: 31977693
[TBL] [Abstract][Full Text] [Related]
2. Using a qualitative approach to conceptualize concerns of patients with neurofibromatosis type 1 associated plexiform neurofibromas (pNF) across the lifespan.
Lai JS; Jensen SE; Patel ZS; Listernick R; Charrow J
Am J Med Genet A; 2017 Jan; 173(1):79-87. PubMed ID: 27666129
[TBL] [Abstract][Full Text] [Related]
3. Pain interference in youth with neurofibromatosis type 1 and plexiform neurofibromas and relation to disease severity, social-emotional functioning, and quality of life.
Wolters PL; Burns KM; Martin S; Baldwin A; Dombi E; Toledo-Tamula MA; Dudley WN; Gillespie A; Widemann BC
Am J Med Genet A; 2015 Sep; 167A(9):2103-13. PubMed ID: 25976979
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of quality of life in adults with neurofibromatosis 1 (NF1) using the Impact of NF1 on Quality Of Life (INF1-QOL) questionnaire.
Ferner RE; Thomas M; Mercer G; Williams V; Leschziner GD; Afridi SK; Golding JF
Health Qual Life Outcomes; 2017 Feb; 15(1):34. PubMed ID: 28193237
[TBL] [Abstract][Full Text] [Related]
5. Pediatric plexiform neurofibromas: impact on morbidity and mortality in neurofibromatosis type 1.
Prada CE; Rangwala FA; Martin LJ; Lovell AM; Saal HM; Schorry EK; Hopkin RJ
J Pediatr; 2012 Mar; 160(3):461-7. PubMed ID: 21996156
[TBL] [Abstract][Full Text] [Related]
6. NF1 mutations in neurofibromatosis 1 patients with plexiform neurofibromas.
Kluwe L; Friedrich RE; Korf B; Fahsold R; Mautner VF
Hum Mutat; 2002 Mar; 19(3):309. PubMed ID: 11857752
[TBL] [Abstract][Full Text] [Related]
7. The PlexiQoL, a patient-reported outcome measure on quality of life in neurofibromatosis type 1-associated plexiform neurofibroma: translation, cultural adaptation and validation into the Dutch language for the Netherlands.
Dhaenens BAE; van Dijk SA; Taal W; Noordhoek DC; Coffey A; McKenna SP; Oostenbrink R
J Patient Rep Outcomes; 2024 Mar; 8(1):33. PubMed ID: 38499890
[TBL] [Abstract][Full Text] [Related]
8. Impact of neurofibromatosis 1 upon quality of life in childhood: a cross-sectional study of 79 cases.
Wolkenstein P; Rodriguez D; Ferkal S; Gravier H; Buret V; Algans N; Simeoni MC; Bastuji-Garin S
Br J Dermatol; 2009 Apr; 160(4):844-8. PubMed ID: 19067713
[TBL] [Abstract][Full Text] [Related]
9. Orbit deformities in craniofacial neurofibromatosis type 1.
Jacquemin C; Bosley TM; Svedberg H
AJNR Am J Neuroradiol; 2003 Sep; 24(8):1678-82. PubMed ID: 13679291
[TBL] [Abstract][Full Text] [Related]
10. Lifespan Development: Symptoms Experienced by Individuals with Neurofibromatosis Type 1 Associated Plexiform Neurofibromas from Childhood into Adulthood.
Jensen SE; Patel ZS; Listernick R; Charrow J; Lai JS
J Clin Psychol Med Settings; 2019 Sep; 26(3):259-270. PubMed ID: 30298332
[TBL] [Abstract][Full Text] [Related]
11. Recommendations for assessing appearance concerns related to plexiform and cutaneous neurofibromas in neurofibromatosis 1 clinical trials.
Merker VL; Thompson HL; Wolters PL; Buono FD; Hingtgen CM; Rosser T; Barton B; Barnett C; Smith T; Haberkamp D; McManus ML; Baldwin A; Moss IP; Röhl C; Martin S
Clin Trials; 2024 Feb; 21(1):6-17. PubMed ID: 38140900
[TBL] [Abstract][Full Text] [Related]
12. The development of the PlexiQoL: A patient-reported outcome measure for adults with neurofibromatosis type 1-associated plexiform neurofibromas.
Heaney A; Wilburn J; Rouse M; Langmead S; Blakeley JO; Huson S; McKenna SP
Mol Genet Genomic Med; 2020 Dec; 8(12):e1530. PubMed ID: 33085177
[TBL] [Abstract][Full Text] [Related]
13. Lymphocyte Subpopulations in Patients With Neurofibromatosis Type 1-associated Optic Pathway Gliomas and Plexiform Neurofibromas.
Marjanska A; Kubicka M; Kurylo-Rafinska B; Jatczak-Gaca A; Wysocki M; Styczynski J
Anticancer Res; 2019 Nov; 39(11):6389-6392. PubMed ID: 31704872
[TBL] [Abstract][Full Text] [Related]
14. Phase II trial of pirfenidone in children and young adults with neurofibromatosis type 1 and progressive plexiform neurofibromas.
Widemann BC; Babovic-Vuksanovic D; Dombi E; Wolters PL; Goldman S; Martin S; Goodwin A; Goodspeed W; Kieran MW; Cohen B; Blaney SM; King A; Solomon J; Patronas N; Balis FM; Fox E; Steinberg SM; Packer RJ
Pediatr Blood Cancer; 2014 Sep; 61(9):1598-602. PubMed ID: 24753394
[TBL] [Abstract][Full Text] [Related]
15. Quality of Life in Children and Adolescents with Neurofibromatosis Type 1: A Single-Center Observational Study.
Hofmann S; Winkler S; Baumann M; Zellner H
Neuropediatrics; 2023 Dec; 54(6):430-432. PubMed ID: 37321252
[TBL] [Abstract][Full Text] [Related]
16. Distinctive epigenomic alterations in NF1-deficient cutaneous and plexiform neurofibromas drive differential MKK/p38 signaling.
Grit JL; Johnson BK; Dischinger PS; J Essenburg C; Adams M; Campbell S; Pollard K; Pratilas CA; Triche TJ; Graveel CR; Steensma MR
Epigenetics Chromatin; 2021 Jan; 14(1):7. PubMed ID: 33436083
[TBL] [Abstract][Full Text] [Related]
17. Identification of potential common genetic modifiers of neurofibromas: a genome-wide association study in 1333 patients with neurofibromatosis type 1.
Pacot L; Sabbagh A; Sohier P; Hadjadj D; Ye M; Boland-Auge A; Bacq-Daian D; Laurendeau I; Briand-Suleau A; Deleuze JF; Margueron R; Vidaud M; Ferkal S; Parfait B; Vidaud D; ; Pasmant E; Wolkenstein P
Br J Dermatol; 2024 Jan; 190(2):226-243. PubMed ID: 37831592
[TBL] [Abstract][Full Text] [Related]
18. Analysis of intratumor heterogeneity in Neurofibromatosis type 1 plexiform neurofibromas and neurofibromas with atypical features: Correlating histological and genomic findings.
Carrió M; Gel B; Terribas E; Zucchiatti AC; Moliné T; Rosas I; Teulé Á; Ramón Y Cajal S; López-Gutiérrez JC; Blanco I; Castellanos E; Lázaro C; Stemmer-Rachamimov A; Romagosa C; Serra E
Hum Mutat; 2018 Aug; 39(8):1112-1125. PubMed ID: 29774626
[TBL] [Abstract][Full Text] [Related]
19. Patient Reported Outcomes Measurement Information System and Quality of Life in Neurological Disorders Measurement System to Evaluate Quality of Life for Children and Adolescents with Neurofibromatosis Type 1 Associated Plexiform Neurofibroma.
Lai JS; Jensen SE; Charrow J; Listernick R
J Pediatr; 2019 Mar; 206():190-196. PubMed ID: 30413310
[TBL] [Abstract][Full Text] [Related]
20. Is a plexiform neurofibroma pathognomonic of neurofibromatosis type I?
Lin V; Daniel S; Forte V
Laryngoscope; 2004 Aug; 114(8):1410-4. PubMed ID: 15280718
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
